Clinical Trial Search

Primary: Number of Participants Who Had an Abnormal Regional Uptake of I-123 mIBG at Baseline (Acute Phase) and the Number of Participants Who Had an Abnormal I-123 mIBG Uptake…

Primary: C Reactive Protein — 2.09; 2.93 days

Primary: Participants With Dose Limiting Toxicity — 0; 2 participants

Primary: Percentage of Subjects With Drug-related Adverse Events — 6.7; 0.0; 0.0; 0.0 percentage of participants

Primary: Percentage of Participants With Pathological Complete Response (pCR) in the Breast and in the Lymph Nodes — 25; 26.3; 46.7 Percentage of participants — p=0.019

Primary: Change From Baseline in Daily Average Frequency of Urinary Incontinence Episodes — 4.18; 4.32; -3.34; -1.10 Episodes

Primary: Number of Patients With Adverse Events as a Measure of Safety and Tolerability — 12; 8; 4; 4 participants

Primary: The Proportion Of Participants With Virologic Response For 10 mg/Day Elvucitabine In HIV-1-Infected Participants By 12 Weeks Compared With The Proportion Of Participants…

Primary: Summed Symptom Severity — 23.2; 19.9 units on a scale — p=0.030

Primary: Mean Change From Baseline to Week 24 in the Scales for Outcomes in Parkinson's Disease-Cognition (SCOPA-COG) Summary Score — 1.6; 0.8 units on a scale — p=0.2204

Primary: Steady State Area Under the Plasma Concentration Versus Time Curve From 0 to 12 Hours After Dosing (AUC0-12) of Oseltamivir and Oseltamivir Carboxylate — 5.092; 5.070…

Primary: Proportion of Patients Who Experienced Moderate to Severe Pain During First and Second Postoperative Day — 8.3; 80.8; 4.2; 42.3 percentage of patients

Primary: Mean Total Restless Leg Syndrome Rating Scale Score — 25.19; 19.46 units on a scale — p=0.031

Primary: Number of Episodes of Catheter Related Blood Stream Infections in Each Study Period. — 6.59; 25.90 number of CRBSI per 1000 catheter days — p=0.012

Primary: Emergency Department Use — 0.1050; 0.0885 Emergency dept use rate per person-month — p=0.017